InvestorsHub Logo
Followers 192
Posts 4375
Boards Moderated 1
Alias Born 08/27/2009

Re: None

Monday, 02/04/2013 5:37:18 PM

Monday, February 04, 2013 5:37:18 PM

Post# of 3329
New Lawsuit! Federman & Sherwood Announces That a Securities Class Action Lawsuit Has Been Filed Against Keryx Biopharmaceuticals, Inc.

These lawsuits are really start to pile up now, I am a strong feeling more will be filed about what the company has done in the last two weeks!

On February 1, 2013, a class action lawsuit was filed in the United States District Court for the Southern District of New York against Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is June 1, 2009 through April 1, 2012.
Plaintiff seeks to recover damages on behalf of all Keryx Biopharmaceuticals, Inc. shareholders who purchased common stock during the Class Period and are therefore a member of the Class as described above. You may move the Court no later than Tuesday, April 2, 2013 to serve as a lead plaintiff for the entire Class. However, in order to do so, you must meet certain legal requirements pursuant to the Private Securities Litigation Reform Act of 1995.

If you wish to discuss this action, obtain further information and participate in this or any other securities litigation, or should you have any questions or concerns regarding this notice or preservation of your rights, please contact:

K. Lynn Nunn

FEDERMAN & SHERWOOD

10205 North Pennsylvania Avenue

Oklahoma City, OK 73120

Email to: kln@federmanlaw.com

Or, visit the firm's website at www.federmanlaw.com


Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.